机构：[1]Department of Psychiatry, Affiliated Hospital of Guangdong Medical College Zhanjiang, China.[2]Department of Pharmacology, Guangdong Medical College Dongguan, China.[3]Department of Neurology, Affiliated Hospital of Guangdong Medical College Zhanjiang, China.[4]Department of Traditional Chinese Medicine, The Second Clinical Medical School, Guangdong Medical College Dongguan, China.[5]Department of Surgery, University of Minnesota Minneapolis, USA.[6]Institute of Traditional Chinese Medicine, Guangdong Medical College Zhanjiang, China.
出处：
ISSN：
摘要：
Adalimumab is used in an attempt to maintain remission for Ulcerative colitis. This study was to evaluate the efficacy and adverse events of adalimumab compared with placebo in inducing remission of Ulcerative colitis.
MEDLINE, EMBASE, the Cochrane Controlled Trials Register, OVID, BIOSIS, CNKI, and Google were searched. All randomized trials comparing adalimumab with placebo in inducing remission of moderate-to-severe ulcerative colitis were included.
Two randomized controlled trials with a total of 754 participants met the inclusion criteria. The pooled risk ratio (RR) of clinical remission was 1.85 (95% confidence interval (CI) 1.26 to 2.72) following adalimumab treatment. RR of clinical response was 1.40 (95% CI 1.19 to 1.65) while that of mucosal healing was 1.23 (95% CI 1.03 to 1.47). RR of any adverse events was 1.00 (95% CI 0.93 to 1.09).
Compared with placebo, administration of adalimumab may increase the proportion of patients with moderate-to-severe ulcerative colitis attaining clinical remission, clinical response and mucosal healing. Adalimumab is also tolerated well in these patients.
基金：
Medical Research Foundation of Guangdong Province (B2014-294), and Scientific Funds of Guangdong Medical College (M2013054).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2014]版：
大类|4 区医学
小类|4 区医学：研究与实验
最新[2025]版：
大类|4 区医学
小类|4 区医学：研究与实验
第一作者：
第一作者机构：[1]Department of Psychiatry, Affiliated Hospital of Guangdong Medical College Zhanjiang, China.
通讯作者：
通讯机构：[6]Institute of Traditional Chinese Medicine, Guangdong Medical College Zhanjiang, China.[*1]In-stitute of Traditional Chinese Medicine, Guangdong Medical College, Zhanjiang, China.
推荐引用方式(GB/T 7714)：
Yang Zheng,Ye Xiao-Qing,Zhu Yu-Zhen,et al.Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis.[J].International journal of clinical and experimental medicine.2015,8(1):86-93.
APA：
Yang Zheng,Ye Xiao-Qing,Zhu Yu-Zhen,Liu Zhou,Zou Ying...&Feng Jin-Shan.(2015).Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis..International journal of clinical and experimental medicine,8,(1)
MLA：
Yang Zheng,et al."Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis.".International journal of clinical and experimental medicine 8..1(2015):86-93
